CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

 

 

 

Alemtuzumab: pharmacology, safety and new possible applications

Author: 
Amelia Morgillo, Edoardo Marovino, Marcello Mazzarella, Ilaria Marotta and Emanuela Genito
Subject Area: 
Health Sciences
Abstract: 

Introduction: Alemtuzumab is a new generation monoclonal antibody with anti-CD52 action and with specific indication for relapsing-remitting multiple sclerosis. In recent years, however, "off-label" applications in the immunological field have begun, such as immunosuppression in transplants or the treatment of other dysimmune diseases. The purpose of this article is, starting from its characteristics, to describe these uses and the tolerability profile. Materials and methods: A computerized search was carried out for the articles inserted through the use of international databases such as pubmed, scopus, researchgate, google scholar, selecting articles about alemtuzumab with particular regard to pharmacovigilance and new off-label applications. The research was carried out by selecting recent articles, obviously also including those relating to authorized uses. We also use the AIFA site and some books for the chapter on pharmacovigilance together with the "codifa" site to evaluate the technical data sheet. Discussion and Conclusion: Alemtuzumab is an interesting drug, very potent and usable for both inducing and maintaining remission from highly active forms of multiple sclerosis. However, induced immuno-reconstitution has prompted researchers to test its use both in the transplant field, especially for the immunosuppression induction regimen in the immediate post-surgical period, and for immuno-manipulation in the management of autoimmune diseases such as some rheumatic forms. refractory to conventional treatments. However, it must be said that safety is not always favorable, as it is associated with two important risks; severe opportunistic infections (including PML) and induction of secondary autoimmunity, particularly on the thyroid gland.

PDF file: 

Announcement

  • FAST PUBLICATION : October 2022
  • IMPACT FACTOR: 7.992
  • QUALIS INDEXING
  • HIGH IMPACT FACTOR
  • INTERNATIONAL JOURNAL OF CURRENT RESEARCH

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran